360 related articles for article (PubMed ID: 35806243)
1. Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted.
Ali R; Aouida M; Alhaj Sulaiman A; Madhusudan S; Ramotar D
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806243
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin in cancer therapy: molecular mechanisms of action.
Dasari S; Tchounwou PB
Eur J Pharmacol; 2014 Oct; 740():364-78. PubMed ID: 25058905
[TBL] [Abstract][Full Text] [Related]
3. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
Bowden NA
Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin: The first metal based anticancer drug.
Ghosh S
Bioorg Chem; 2019 Jul; 88():102925. PubMed ID: 31003078
[TBL] [Abstract][Full Text] [Related]
5. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Mello JA; Acharya S; Fishel R; Essigmann JM
Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890
[TBL] [Abstract][Full Text] [Related]
6. Cellular and molecular determinants of cisplatin resistance.
Perez RP
Eur J Cancer; 1998 Sep; 34(10):1535-42. PubMed ID: 9893624
[TBL] [Abstract][Full Text] [Related]
7. [Advances of DNA damage repair and Cisplatin resistance mechanisms in lung cancer].
Tang C; Yang H; Zhou X
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):960-4. PubMed ID: 22152698
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
Ferguson PJ; Currie C; Vincent MD
Drug Metab Dispos; 1999 Dec; 27(12):1399-405. PubMed ID: 10570020
[TBL] [Abstract][Full Text] [Related]
9. Systems biology of cisplatin resistance: past, present and future.
Galluzzi L; Vitale I; Michels J; Brenner C; Szabadkai G; Harel-Bellan A; Castedo M; Kroemer G
Cell Death Dis; 2014 May; 5(5):e1257. PubMed ID: 24874729
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
Makovec T
Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
[TBL] [Abstract][Full Text] [Related]
11. The role of DNA repair pathways in cisplatin resistant lung cancer.
O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP
Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603
[TBL] [Abstract][Full Text] [Related]
12. [Molecular bases of platinum-resistance in testicular cancer].
Germà-Lluch JR; Piulats JM
Arch Esp Urol; 2013 Jun; 66(5):524-35. PubMed ID: 23793770
[TBL] [Abstract][Full Text] [Related]
13. DNA repair pathways and cisplatin resistance: an intimate relationship.
Rocha CRR; Silva MM; Quinet A; Cabral-Neto JB; Menck CFM
Clinics (Sao Paulo); 2018 Sep; 73(suppl 1):e478s. PubMed ID: 30208165
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin.
Trimmer EE; Essigmann JM
Essays Biochem; 1999; 34():191-211. PubMed ID: 10730196
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions.
Zoń A; Bednarek I
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108749
[TBL] [Abstract][Full Text] [Related]
16. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
17. Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.
Nijwening JH; Kuiken HJ; Beijersbergen RL
Cell Cycle; 2011 Feb; 10(3):380-6. PubMed ID: 21239890
[TBL] [Abstract][Full Text] [Related]
18. Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches.
Yue P; Han B; Zhao Y
Mol Omics; 2023 May; 19(4):297-307. PubMed ID: 36723121
[TBL] [Abstract][Full Text] [Related]
19. Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer.
Berkel C; Cacan E
Life Sci; 2021 Dec; 286():120029. PubMed ID: 34634322
[TBL] [Abstract][Full Text] [Related]
20. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.
Pratesi G; Perego P; Polizzi D; Righetti SC; Supino R; Caserini C; Manzotti C; Giuliani FC; Pezzoni G; Tognella S; Spinelli S; Farrell N; Zunino F
Br J Cancer; 1999 Aug; 80(12):1912-9. PubMed ID: 10471039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
